ISTH 0036Alternative Names: ISTH0036
Latest Information Update: 09 May 2016
At a glance
- Originator Isarna Therapeutics
- Class Antiglaucomas; Antisense oligonucleotides
- Mechanism of Action Transforming growth factor beta2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glaucoma